BiotechTubeBiotechTube
Home/Asher Biotherapeutics/Edward Garmey, MD
EG

Edward Garmey, MD

Consulting Chief Medical Officer

Asher Biotherapeutics

Therapeutic Areas

OncologyInfectious Diseases

Asher Biotherapeutics Pipeline

DrugIndicationPhase
Etakafusp alfa (AB248)Recurrent locally advanced or metastatic solid tumors (Melanoma, RCC, NSCLC, SCCHN)Phase 1a/1b
AB821Oncology (Solid Tumors)Preclinical
Undisclosed Cis-Targeted ProgramsOncology & Infectious DiseasesPreclinical

Leadership Team at Asher Biotherapeutics

ID
Ivana Djuretic, PhD
Founder, Chief Executive Officer
View full Asher Biotherapeutics profile